Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · IEX Real-Time Price · USD
2.560
-0.100 (-3.76%)
Apr 19, 2024, 3:59 PM EDT - Market closed

Company Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.

The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd.
Alpha Tau Medical logo
Country Israel
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 121
CEO Uzi Sofer

Contact Details

Address:
Kiryat Hamada 5
Jerusalem, L3 9777605
Israel
Phone 972-3-577-4115
Website alphatau.com

Stock Details

Ticker Symbol DRTS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001871321
CUSIP Number M0740A108
ISIN Number IL0011839383
SIC Code 3841

Key Executives

Name Position
Uzi Sofer Chief Executive Officer and Chairman
Raphi Levy Chief Financial Officer
Amnon Gat Chief Operations Officer
Peter M. Melnyk Chief Commercial Officer
Dr. Robert B. Den M.D. Chief Medical Officer and Member of Scientific Advisory Board
Ronen Segal Chief Technology Officer
Prof. Yona Keisari Chief Scientific Officer and Member of Scientific Advisory board
Rebecca Becker Vice President of legal
Prof. Itzhak Kelson Chief Physics Officer and Member of Scientific Advisory Board
Yael Zeiger Corporate Controller

Latest SEC Filings

Date Type Title
Mar 25, 2024 6-K Report of foreign issuer
Mar 15, 2024 144 Filing
Mar 7, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 7, 2024 6-K Report of foreign issuer
Mar 7, 2024 20-F Annual and transition report of foreign private issuers
Feb 26, 2024 6-K Report of foreign issuer
Dec 20, 2023 6-K Report of foreign issuer
Dec 18, 2023 144 Filing
Nov 29, 2023 6-K Report of foreign issuer
Nov 28, 2023 6-K Report of foreign issuer